Title |
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
|
---|---|
Published in |
Cardiovascular Diabetology, July 2013
|
DOI | 10.1186/1475-2840-12-100 |
Pubmed ID | |
Authors |
Eliot A Brinton, Christie M Ballantyne, Harold E Bays, John J Kastelein, Rene A Braeckman, Paresh N Soni |
Abstract |
Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (>=500 mg/dL) hypertriglyceridemia. ANCHOR was a 12-week, phase 3 study that evaluated the efficacy and safety of IPE in patients (N = 702) with residual high fasting TG levels (>=200 and <500 mg/dL) despite having optimized low-density lipoprotein cholesterol (LDL-C) levels (>=40 and <100 mg/dL) on statin therapy. Among patients randomized to IPE (4 g/day or 2 g/day) or placebo, 514 (73%) had diabetes mellitus. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Romania | 1 | <1% |
Canada | 1 | <1% |
Unknown | 104 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 18 | 17% |
Researcher | 13 | 12% |
Student > Master | 11 | 10% |
Student > Ph. D. Student | 8 | 8% |
Student > Postgraduate | 7 | 7% |
Other | 15 | 14% |
Unknown | 34 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 32 | 30% |
Biochemistry, Genetics and Molecular Biology | 12 | 11% |
Nursing and Health Professions | 7 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
Agricultural and Biological Sciences | 3 | 3% |
Other | 12 | 11% |
Unknown | 36 | 34% |